Association of Circulating Sex Hormones With Inflammation and Disease Severity in Patients With COVID-19

• Published in: JAMA network open 2021-05, Vol.4 (5), p.e2111398-e2111398
• Main Authors: Dhindsa, Sandeep, Zhang, Nan, McPhaul, Michael J, Wu, Zengru, Ghoshal, Amit K, Erlich, Emma C, Mani, Kartik, Randolph, Gwendalyn J, Edwards, John R, Mudd, Philip A, Diwan, Abhinav
• Format: Article
• Language: English
• Subjects: Aged; Coronaviruses; COVID-19; COVID-19 - blood; COVID-19 - complications; COVID-19 - pathology; Cytokines; Diabetes and Endocrinology; Estradiol - blood; Female; Gonadal Steroid Hormones - blood; Growth factors; Hormones; Hospitalization; Hospitals; Humans; Inflammation - blood; Inflammation - etiology; Insulin-Like Growth Factor I - metabolism; Male; Middle Aged; Missouri; Online Only; Original Investigation; SARS-CoV-2; Severity of Illness Index; Sex Factors; Testosterone; Testosterone - blood
• ISSN: 2574-3805; 2574-3805
• DOI: 10.1001/jamanetworkopen.2021.11398

Male sex is a risk factor for developing severe COVID-19 illness. It is not known whether sex hormones contribute to this predisposition. To investigate the association of concentrations of serum testosterone, estradiol, and insulinlike growth factor 1 (IGF-1, concentrations of which are regulated by sex hormone signaling) with COVID-19 severity. This prospective cohort study was conducted using serum samples collected from consecutive patients who presented from March through May 2020 to the Barnes Jewish Hospital in St Louis, Missouri, with COVID-19 (diagnosed using nasopharyngeal swabs). Testosterone, estradiol, and IGF-1 concentrations were measured at the time of presentation (ie, day 0) and at days 3, 7, 14, and 28 after admission (if the patient remained hospitalized). Baseline hormone concentrations were compared among patients who had severe COVID-19 vs those with milder COVID-19 illness. RNA sequencing was performed on circulating mononuclear cells to understand the mechanistic association of altered circulating hormone concentrations with cellular signaling pathways. Among 152 patients (90 [59.2%] men; 62 [40.8%] women; mean [SD] age, 63 [16] years), 143 patients (94.1%) were hospitalized. Among 66 men with severe COVID-19, median [interquartile range] testosterone concentrations were lower at day 0 (53 [18 to 114] ng/dL vs 151 [95 to 217] ng/dL; P = .01) and day 3 (19 [6 to 68] ng/dL vs 111 [49 to 274] ng/dL; P = .006) compared with 24 men with milder disease. Testosterone concentrations were inversely associated with concentrations of interleukin 6 (β = -0.43; 95% CI, -0.52 to -0.17; P